Lisinopril chf
Pro Research Analysisby 
Searched over 200M research papers for "lisinopril chf"
Consensus Meter
Lisinopril in the Treatment of Congestive Heart Failure (CHF)
Pharmacokinetics of Lisinopril in CHF Patients
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, exhibits altered pharmacokinetics in patients with congestive heart failure (CHF). Studies have shown that the absorption of lisinopril is significantly reduced in CHF patients compared to normal subjects, with a mean urinary recovery of 15% following oral administration and 88% following intravenous administration . This reduced absorption is likely due to the disease state and possibly age-related factors. Despite lower absorption, serum concentrations of lisinopril are higher in CHF patients after intravenous administration, indicating altered drug disposition in this population .
Efficacy of Lisinopril in Improving CHF Symptoms
Lisinopril has been demonstrated to significantly improve clinical outcomes in CHF patients. In a 12-week randomized, double-blind trial involving 130 patients, lisinopril improved exercise duration, left ventricular ejection fraction (LVEF), and clinical signs and symptoms of CHF compared to placebo. Additionally, lisinopril was found to increase maximal oxygen uptake in CHF patients, further supporting its efficacy in enhancing physical performance.
Comparison with Other ACE Inhibitors and ARBs
When compared to other ACE inhibitors like captopril, lisinopril has shown comparable or superior efficacy. Both drugs increased treadmill exercise times in CHF patients, but lisinopril was more effective in patients with renal impairment and improved LVEF, unlike captopril . In a study comparing lisinopril with the angiotensin II receptor blocker (ARB) valsartan, both drugs showed similar effects on left ventricular function and autonomic control of heart rate. However, valsartan was more effective in reducing plasma norepinephrine levels, indicating better modulation of sympathetic activity.
Safety and Tolerability of Long-term Lisinopril Use
Long-term use of lisinopril in CHF patients has been generally well tolerated. In a study involving over 1,000 patients, the most common adverse events were dizziness, dyspnea, diarrhea, hypotension, and fatigue . Approximately 33% of patients discontinued treatment over a four-year period, with clinical adverse events and unrelated reasons being the primary causes. The safety profile of lisinopril is similar to other ACE inhibitors, with common side effects including increases in blood urea nitrogen, serum creatinine, and plasma potassium .
Hemodynamic and Hormonal Effects
Lisinopril has significant hemodynamic and hormonal effects in CHF patients. It reduces mean arterial pressure, mean pulmonary capillary wedge pressure, and systemic vascular resistance without significantly affecting heart rate or cardiac index. Additionally, lisinopril effectively inhibits the renin-angiotensin-aldosterone system, leading to potent ACE inhibition and hemodynamic efficacy for over 24 hours.
Conclusion
Lisinopril is a valuable ACE inhibitor for the treatment of congestive heart failure, offering significant improvements in exercise capacity, LVEF, and overall clinical symptoms. Its pharmacokinetics are altered in CHF patients, necessitating careful monitoring. Long-term use is generally safe and well-tolerated, with a side effect profile similar to other ACE inhibitors. Lisinopril's efficacy in improving hemodynamic parameters and inhibiting the renin-angiotensin-aldosterone system makes it a crucial component in the management of CHF.
Sources and full results
Most relevant research papers on this topic